Stoke Therapeutics (STOK) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 3, 2026, with virtual attendance available for shareholders.

• Shareholders are encouraged to review proxy materials and vote by June 2, 2026.

Voting matters and shareholder proposals

• Election of three Class I directors to serve until the 2029 annual meeting or until successors are elected.

• Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.

• Advisory vote to approve compensation of named executive officers.

• Board recommends voting in favor of all proposals.

Board of directors and corporate governance

• Nominees for Class I director positions are G. Clare Kahn, Ph.D., Adrian Krainer, Ph.D., and Julie Anne Smith.